| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Apr―21 |
Immunomodulator therapies in pandemics: lessons from COVID-19 and a blueprint for future outbreaks |
Matthew W. McCarthy |
| 2 |
[GO] |
2024―Aug―01 |
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19 |
Arturo Casadevall, Scott McConnell, Daniele Focosi |
| 3 |
[GO] |
2024―Mar―04 |
Emerging anti-spike monoclonal antibodies against SARS-CoV-2 |
Eloy E. Ordaya, Raymund R. Razonable |
| 4 |
[GO] |
2023―Dec―15 |
Intravenous immunoglobulin as a potential treatment for long COVID |
Matthew W McCarthy |
| 5 |
[GO] |
2023―Jul―08 |
Optimizing the use of vilobelimab for the treatment of COVID-19 |
Matthew W McCarthy |
| 6 |
[GO] |
2023―Jun―15 |
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions |
Raymund R Razonable |
| 7 |
[GO] |
2023―May―06 |
Interferon lambda as a potential treatment for COVID-19 |
Matthew W McCarthy |
| 8 |
[GO] |
2023―Apr―19 |
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT |
Raveendra KR, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, Radhika A, Ashwani Marwah, Nitin M Chaudhari, Binay K Thakur, Sivakumar Vaidyanathan, Sandeep Nilkanth Athalye |
| 9 |
[GO] |
2023―Jan―03 |
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity |
Ileana García-Silva, Dania O Govea-Alonso, Sergio Rosales-Mendoza |
| 10 |
[GO] |
2022―Oct―15 |
Original antigen sin and COVID-19: implications for seasonal vaccination |
Matthew W McCarthy |
| 11 |
[GO] |
2022―Aug―05 |
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis |
Paolo Gisondi, Davide Geat, Francesco Bellinato, Giampiero Girolomoni |
| 12 |
[GO] |
2022―May―23 |
Therapeutic monoclonal antibodies for COVID-19 management: an update |
Vivek P Chavda, Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M Redwan, Vladimir N Uversky, Mukesh N Kher, Patel Rajvi |
| 13 |
[GO] |
2022―Apr―29 |
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease |
Lucia Trotta, Massimo Pancrazi, Emanuele Bizzi, Enrico Tombetti, Ruggiero Mascolo, Giada Pallini, Alveena Batool Syed, Martin Lewinter, Allan Klein, Antonio Luca Brucato |
| 14 |
[GO] |
2021―Sep―24 |
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? |
Sheila A Doggrell |
| 15 |
[GO] |
2021―Aug―06 |
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents |
Marina Talamonti, Marco Galluzzo |
| 16 |
[GO] |
2021―Apr―22 |
Immunomodulatory Extracellular Vesicles: An alternative to cell therapy for COVID-19 |
Ashim Gupta, Shivaji Kashte, Sachin Kadam, Manu Gupta, Hugo C. Rodriguez, Anish G. Potty, Saadiq F. El-Amin III, Nicola Maffulli |
| 17 |
[GO] |
2021―Apr―09 |
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 |
Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye |
| 18 |
[GO] |
2021―Feb―06 |
Immune Checkpoint Inhibition in COVID-19: Risks and Benefits |
Parmida Sadat Pezeshki, Nima Rezaei |
| 19 |
[GO] |
2021―Jan―28 |
Tocilizumab for the treatment of COVID-19 |
Mario Fernández-Ruiz, Francisco López-Medrano, José María Aguado |
| 20 |
[GO] |
2020―Nov―20 |
Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study |
Marina Talamonti, Marco Galluzzo, Andrea Chiricozzi, Pietro Quaglino, Gabriella Fabbrocini, Paolo Gisondi, Angelo Valerio Marzano, Concetta Potenza, Andrea Conti, Aurora Parodi, Stefano Piaserico, Federico Bardazzi, Giuseppe Argenziano, Franco Rongioletti, Luca Stingeni, Giuseppe Micali, Francesco Loconsole, Maria Teresa Rossi, Maria Rita Bongiorno, Claudio Feliciani, Pietro Rubegni, Paolo Amerio, Maria Concetta Fargnoli, Paolo Pigatto, Paola Savoia, Steven Paul Nisticò, Sandra Giustini, Andrea Carugno, Serafinella Patrizia Cannavo’, Giulia Rech, Francesca Prignano, Annamaria Offidani, Maurizio Lombardo, Iris Zalaudek, Luca Bianchi, Ketty Peris |
| 21 |
[GO] |
2020―Nov―07 |
A Comprehensive Review on Sarilumab in COVID-19 |
Sajad Khiali, Afra Rezagholizadeh, Taher Entezari-Maleki |
| 22 |
[GO] |
2020―Aug―31 |
The effect of drugs used in rheumatology for treating SARS-CoV2 infection |
Fabiola Atzeni, Elisabetta Gerratana, Manuela Giallanza, Laura La Corte, Valeria Nucera, Gianfranco Miceli, Donatella Sangari, Ignazio Francesco Masala |
| 23 |
[GO] |
2020―Aug―12 |
Host-directed therapies: a potential solution to combat COVID-19 |
Piyush Baindara, Sonali Agrawal, Santi M. Mandal |
| 24 |
[GO] |
2020―Aug―08 |
Immunotherapy for SARS-CoV-2: Potential Opportunities |
Mehrnoosh Pashaei, Nima Rezaei |
| 25 |
[GO] |
2020―Aug―03 |
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects |
Khan Sharun, Ruchi Tiwari, Mohd. Iqbal Yatoo, Shailesh Kumar Patel, Senthilkumar Natesan, Jaideep Dhama, Yashpal S. Malik, Harapan Harapan, Raj Kumar Singh, Kuldeep Dhama |
| 26 |
[GO] |
2020―Jul―23 |
Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications |
Subramanian Loganathan, Sandeep N. Athalye, Shashank R. Joshi |
| 27 |
[GO] |
2020―Jun―26 |
COVID-19 Pneumonia and Immune-Related Pneumonitis: critical issues on differential diagnosis, potential interactions and management |
Marco Russano, Fabrizio Citarella, Andrea Napolitano, Emanuela Dell’Aquila, Alessio Cortellini, Francesco Pantano, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini |
| 28 |
[GO] |
2020―Jun―08 |
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era |
Marco Galluzzo, Lorenzo Tofani, Luca Bianchi, Marina Talamonti |
| 29 |
[GO] |
2020―May―14 |
Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces |
Miguel A. González-Gay, José Mayo, Santos Castañeda, José M. Cifrián, José Hernández-Rodríguez |
| 30 |
[GO] |
2020―May―08 |
Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? |
Leticia Moreno-Fierros, Ileana García-Silva, Sergio Rosales-Mendoza |
| 31 |
[GO] |
2020―Apr―24 |
Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |
Pietro Gentile, Aris Sterodimas |
| 32 |
[GO] |
2020―Apr―06 |
Will plant-made biopharmaceuticals play a role in the fight against COVID-19? |
Sergio Rosales-Mendoza |
